Results 71 to 80 of about 35,569 (305)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Clinical Hypertension
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension.
Hae Young Lee, Seung-Hyun Ko, Sungjoon Park, Kyuho Kim, Song-Yi Kim, In-Jeong Cho, Eun Joo Cho, Hyeon Chang Kim, Jae-Hyeong Park, Sung Kee Ryu, Min Kyong Moon, Sang-Hyun Ihm, the Korean Society of Hypertension   +12 more
doaj   +1 more source

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

, 2015
Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-
Shyangdan DS, O’Hare JP, Gurung T, Waugh N   +3 more
core  

Policy Progress in Using Economic Policy Instruments to Improve Nutrition: Challenges and Opportunities

Health Economics, EarlyView.
ABSTRACT Economic policy can be a powerful instrument to influence food environments and support improved diets and health. Over the past 20 years, the use of fiscal policy to improve diets has increased dramatically. This paper reviews the trajectory of policy change, and explores the ways in which research has informed three different dimensions of ...
Anne Marie Thow
wiley   +1 more source

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain

Neural Regeneration Research
The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, José Antonio Lamas, Lucas C González-Matías, Federico Mallo   +5 more
doaj   +1 more source

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease [PDF]

, 2008
Background It has recently become apparent that neuroinflammation may play a significant role in Parkinson's disease (PD). This is also the case in animal paradigms of the disease.
Rebecca Lever, Peter S Whitton, Abuirmeileh, A., Lever, R., Amjad Abuirmeileh, Harkavyi Alexander, Alexander Harkavyi, Harkavyi, A., Ann E Kingsbury, Abuirmeileh Amjad, Biggs Christopher S, Whitton, P.S., Kingsbury, A.E., Christopher S Biggs, Lever Rebecca, Whitton Peter S, Kingsbury Ann E, Biggs, C.S.   +17 more
core   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

GLP-1 and Its Role in Glycogen Production: A Narrative Review

Biomedicines
Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky, Xavier Jean, Anungoo Altankhuyag, Saqib Khan, Ashley Bernotas, Alireza Sharafshah, Kenneth Blum, Alan Posner, Panayotis K. Thanos   +8 more
doaj   +1 more source

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]

Clinical and Molecular Hepatology
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj   +1 more source

Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists

Journal of the American College of Cardiology, 2019
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of incretin mimetics with multisystem cardiometabolic effects. Six GLP-1RAs are approved for improving glycemic control by the U.S. Food and Drug Administration (FDA).
Muthiah, Vaduganathan, Ravi B, Patel, Avinainder, Singh, Cian P, McCarthy, Arman, Qamar, James L, Januzzi, Benjamin M, Scirica, Javed, Butler, Christopher P, Cannon, Deepak L, Bhatt   +9 more
openaire   +2 more sources